Health insurers slide after proposed 2027 Medicare Advantage payment increase disappoints
A far smaller-than-expected proposed increase in Medicare Advantage payments for 2027 rattled health insurers, raising concerns about benefit design, premiums, and margins in a program serving tens of millions of Americans.
A rate proposal that shocked the market
Shares of major U.S. health insurers fell after the Trump administration proposed a smaller-than-expected increase in payment rates for Medicare Advantage plans in 2027. The proposal pointed to a roughly flat increase—about 0.09%—which would translate into roughly $700 million in additional payments, well below what many analysts had anticipated.
Medicare Advantage is the privately run alternative to traditional Medicare and covers a large and growing share of older and disabled Americans. Because insurer revenue in the program is heavily shaped by federal payment formulas, even modest changes in proposed rates can swing market expectations quickly.
Why payment rates matter for patients
Although the announcement is a policy and finance story, the downstream effects can touch beneficiaries. When payments rise more slowly than medical costs, insurers often respond through plan design: narrowing provider networks, changing prior-authorization rules, adjusting supplemental benefits, or increasing premiums and out-of-pocket costs.
Industry groups and analysts warned that a rate path that fails to keep up with cost trends could pressure margins and lead to benefit reductions in some markets. Companies also face strategic decisions about whether to scale back offerings in counties where profitability becomes harder to sustain.
What comes next in the process
The proposed rate is not necessarily final. The Centers for Medicare & Medicaid Services can revise the numbers before issuing a final rule later in the year, after feedback from insurers, providers, and consumer advocates. Still, the initial proposal often sets expectations and signals the administration’s priorities.
For now, the market reaction highlights the stakes: Medicare Advantage pricing decisions for 2027 will be made in an environment where medical-cost utilization has been elevated, and where policy makers face pressure to control overall healthcare spending while protecting beneficiary access and affordability.